Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Type 1 Diabetes peptide trials
9 selected ClinicalTrials.gov records carrying the official condition label Type 1 Diabetes. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
9 selected records.
6 profiles.
2016–2026 in selected records.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 243 selected PubMed records and 27 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Type 1 Diabetes unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT04449692
PeptideScanner retained ClinicalTrials.gov record NCT04449692 at 2026-11-16T01:42:39.027Z. Its registry update date was 2021-02-09, and PeptideScanner's reviewed identity mapping was dasiglucagon.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- February 9, 2021
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT04764968
PeptideScanner retained ClinicalTrials.gov record NCT04764968 at 2026-11-16T01:42:39.027Z. Its registry update date was 2022-09-07, and PeptideScanner's reviewed identity mapping was dasiglucagon.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- September 7, 2022
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT05378672
PeptideScanner retained ClinicalTrials.gov record NCT05378672 at 2026-11-16T01:42:39.027Z. Its registry update date was 2025-07-20, and PeptideScanner's reviewed identity mapping was dasiglucagon.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- July 20, 2025
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Mazdutide · 2026-11-09
ClinicalTrials.gov record NCT07924553
Not yet recruiting at the retained observation.
Open attributed record →Semaglutide · 2026-10-23
ClinicalTrials.gov record NCT07891156
Recruiting at the retained observation.
Open attributed record →Liraglutide · 2026-10-19
ClinicalTrials.gov record NCT06976619
Recruiting at the retained observation.
Open attributed record →Dasiglucagon · 2025-07-20
ClinicalTrials.gov record NCT05378672
Completed at the retained observation.
Open attributed record →Pramlintide · 2023-10-25
ClinicalTrials.gov record NCT05199714
Completed at the retained observation.
Open attributed record →Dasiglucagon · 2022-09-07
ClinicalTrials.gov record NCT04764968
Completed at the retained observation.
Open attributed record →Dasiglucagon · 2021-02-09
ClinicalTrials.gov record NCT04449692
Completed at the retained observation.
Open attributed record →Cetrorelix · 2020-06-05
ClinicalTrials.gov record NCT04418908
Completed at the retained observation.
Open attributed record →Pramlintide · 2016-07-14
ClinicalTrials.gov record NCT00206297
Completed at the retained observation.
Open attributed record →